+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lung Cancer"

From
From
From
From
From
Non-Small Cell Lung Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

Non-Small Cell Lung Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
HER2+ Non Small Cell Lung Cancer - Epidemiology Forecast - 2032 - Product Thumbnail Image

HER2+ Non Small Cell Lung Cancer - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Small Cell Lung Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

Small Cell Lung Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

Lung cancer is a type of cancer that originates in the lungs. It is the leading cause of cancer-related death worldwide. Oncology is the branch of medicine that deals with the diagnosis, treatment, and prevention of cancer. Lung cancer is one of the most common types of cancer treated by oncologists. Treatment options for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. The lung cancer market is a rapidly growing segment of the oncology market. It is driven by the increasing prevalence of lung cancer, advances in treatment options, and the increasing availability of targeted therapies. The market is expected to continue to grow in the coming years due to the increasing demand for better treatments and the development of new therapies. Some companies in the lung cancer market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more